These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23221858)

  • 21. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
    Alderman J; Preskorn SH; Greenblatt DJ; Harrison W; Penenberg D; Allison J; Chung M
    J Clin Psychopharmacol; 1997 Aug; 17(4):284-91. PubMed ID: 9241008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
    Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects.
    Nichols AI; Lubaczewski S; Liang Y; Matschke K; Braley G; Ramey T
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):830-41. PubMed ID: 25138680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
    Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
    Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6.
    Bergmann TK; Bathum L; Brosen K
    Eur J Clin Pharmacol; 2001 May; 57(2):123-7. PubMed ID: 11417443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
    Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
    J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
    Tourian K; Wang Y; Ii Y
    Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
    Khan AY; Preskorn SH; Horst WD
    J Pak Med Assoc; 2007 May; 57(5):230-5. PubMed ID: 17571477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.
    Furman KD; Grimm DR; Mueller T; Holley-Shanks RR; Bertz RJ; Williams LA; Spear BB; Katz DA
    Pharmacogenetics; 2004 May; 14(5):279-84. PubMed ID: 15115913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenobarbital induces the 2-hydroxylation of desipramine.
    Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
    Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing rapid metabolizers of antidepressants.
    Kraus RP; Diaz P; McEachran A
    Depress Anxiety; 1996-1997; 4(6):320-7. PubMed ID: 9166660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.
    Findling RL; Groark J; Tourian KA; Ramaker SA; Chiles D; Yang L; Nichols AI
    J Child Adolesc Psychopharmacol; 2016 Dec; 26(10):909-921. PubMed ID: 27428303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
    Teng R; Kujacic M; Hsia J
    Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.